Jaguar Health, Inc. (JAGX) Form 8-K — Sep 15, 2026
Jaguar Health's 8-K discloses a wave of privately negotiated equity exchanges: the company issued 557,377 shares to Lincoln Alternative Strategies LLC on September 11, 2026 to retire a 6% convertible note with an outstanding balance of $175,016.36, and issued 304,473 shares to Streeterville Capital across three exchange agreements to cancel 9.2 shares of Series Q Perpetual Preferred Stock. The filing states that the first two Streeterville exchanges alone resulted in the issuance of more than 5% of the company's outstanding common stock as last reported in the 10-Q filed August 19, 2026, making this a heavily dilutive series of unregistered equity sales.
Key figures
- Interest Rate
- 6
- Las exchange shares
- 557377
- Prefunded warrant shares
- 2077255
- Original note principal usd
- 150004.04
- Purchase agreement common shares
- 535000
- Beneficial ownership limitation pct
- 9.99
- Streeterville first exchange shares
- 53191
- Streeterville third exchange shares
- 31847
- Streeterville second exchange shares
- 219435
- Napo therapeutics consideration shares
- 284653
- Prefunded warrant exercise price per share
- 0.0001
- Streeterville exchanges pct of shares outstanding
- more than 5%
- Napo therapeutics shares held by napo pharmaceuticals
- 4155214
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.